about
'Acute myeloid leukemia: a comprehensive review and 2016 update'Secondary mutations as mediators of resistance to targeted therapy in leukemiaPlatelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.The Cytokine Flt3-Ligand in Normal and Malignant HematopoiesisMolecular therapy for acute myeloid leukaemia.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemiaOvercoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy.Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220).Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors.Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cellsIdentification of an orally available compound with potent and broad FLT3 inhibition activityCharacterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitorsThe MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.Acute myeloid leukemia: advancing clinical trials and promising therapeutics.FLT3 inhibitors: clinical potential in acute myeloid leukemia.FLT3 inhibitors in AML: are we there yet?Targeting FLT3 to treat leukemia.New treatment for acute myelogenous leukemia.Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.The safety of treatment options for elderly people with acute myeloid leukemia.Frontline treatment of acute myeloid leukemia in adults.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.Treatment of Elderly Patients With Acute Myeloid Leukemia.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.Leukemogenic potency of the novel FLT3-N676K mutant.Molecular targeting in acute myeloid leukemiaCharacterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivoSynergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation.Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia.Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia.Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations.Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib.
P2860
Q28072539-7589E686-5B47-4F0D-8BAE-72F8E3151D72Q28087213-22733C42-7C7D-4248-996B-46ED335B9710Q30250273-BBBE815E-D412-4EDA-9E8F-BA68D81F3B26Q33749036-79992F9F-F876-4C8D-8176-C56BC2378B7FQ33767026-1AC34A3C-F447-4D82-B486-3CE8CEF7CFF9Q33838356-942E31EB-2D7B-4BC1-B806-EC0912009993Q33925672-FC30D22C-6F44-493E-8872-FF9CA7954AFFQ33943277-F2D32205-4470-4C2F-B75B-6F155BC35CAEQ35016157-46D75473-CB94-4F37-81C5-DD141AF5D531Q35250091-2BE9DFA1-285B-4D08-B922-F3E343FAF879Q35576181-7780CCF4-ED56-40F2-9477-2063C5EE8116Q35685058-99B74557-DCB0-4D13-8C36-7F8FEA3DB882Q35789739-31520E83-4B7F-4B80-87D4-07F8C7538103Q35909096-B5FD501E-0C99-4CF3-A60D-0DE8E05AA41FQ36276942-EB2FF94E-DA46-44DC-B2C9-AD36239711A7Q36362951-F2B9DE9F-35F1-4EFE-BDF8-495FFF889474Q36865880-DB60FC63-281D-44D5-BA58-5FF6EFAA1EFDQ37221579-F0551ACB-D9DE-4804-8DAD-00A742C4C107Q37638749-69C471CE-C026-46E3-BDDA-7F1CF15E0C1DQ38200564-CD3A7A14-350E-440F-B8C7-9BC47B4FCCABQ38251339-D649A1C7-ADBB-4B03-92BE-846A4B8700B0Q38284045-07696847-17FA-48A3-8E65-2216281313CBQ38428692-D6D9D53A-0B19-4917-90E7-D003D293EF92Q38666159-67E0385A-5CF0-495E-9F94-5F849DF77808Q38721796-927332D3-3AE0-4570-8FA0-5AEEAD6DAC82Q38760822-DE368E5C-F5DC-4FA3-BE12-A74264FA0292Q38767583-5F67A33B-1E2B-4FED-A1A9-EA2A9A29BDBAQ38989374-113177B5-35EE-4D47-90FA-5BE18B1F4A83Q39112940-FAAD7645-BF2E-4717-AB98-9756FC568790Q39175665-A9DB92FD-EF22-4795-A7B2-D4519EDB08FBQ40207115-4288AD19-4DFE-49C9-A273-809BFB650E79Q40901421-C24C974F-8876-4A4D-A1A5-ACC8EBEF1451Q41558732-ECDB5624-8EBA-4E29-9501-F1D43987FB16Q41592581-8EF86B5E-6964-43FB-9D25-933545F3694FQ41949145-F0BDE657-E793-4F3F-82FB-55E3A42A0EACQ42265653-A7F4137E-CF80-4251-81C4-043A0D5FA0C0Q47150923-6575B5D0-917B-487E-A5AC-539E610306D2Q47161255-CDE89260-986E-474D-9C03-C94BCBFE290BQ47439297-1458C975-0E01-4710-BA31-861C0B5BFF33Q48263650-9065713D-733E-431C-9053-68E8B7818B2F
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Crenolanib is a selective type I pan-FLT3 inhibitor
@en
Crenolanib is a selective type I pan-FLT3 inhibitor.
@nl
type
label
Crenolanib is a selective type I pan-FLT3 inhibitor
@en
Crenolanib is a selective type I pan-FLT3 inhibitor.
@nl
prefLabel
Crenolanib is a selective type I pan-FLT3 inhibitor
@en
Crenolanib is a selective type I pan-FLT3 inhibitor.
@nl
P2093
P2860
P356
P1476
Crenolanib is a selective type I pan-FLT3 inhibitor
@en
P2093
Alexander E Perl
Catherine Choy Smith
Elisabeth A Lasater
John Kuriyan
Kimberly C Lin
Lauren E Damon
Martin Carroll
Mayumi Sugita
Melissa Quino McCreery
Neil P Shah
P2860
P304
P356
10.1073/PNAS.1320661111
P407
P577
2014-03-12T00:00:00Z